Fig. 7.

MPZL3 levels correlate with MET and ERBB3 gene expression and are associated with poor clinical outcome in gastric cancers. a–c Correlation between the indicated genes in gastric tumors, estimated using Pearson’s correlation (n = 300). d Expression of MPZL3 in normal gastric tissues (n = 100) and gastric tumors (n = 300). e Expression of MPZL3 across gastric cancer subtypes. EMT, Epithelial-mesenchymal transition (n = 46); MSI, microsatellite instability (n = 68); MSS, microsatellite stable; TP53^–, TP53 loss (n = 107); TP53⁺, TP53 intact (n = 79). f Recurrence-free survival across gastric intestinal adenocarcinoma according to Lauren classification (n = 107). Data from GSE66229. Student’s t test; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001